Cell & Molecular Biology of Prostate Cancer


Book Description

This volume covers classic and modern cell and molecular biology of prostate cancer, as well as novel biomarkers, inflammation, centrosome pathologies, microRNAs, cancer initiation novel biomarkers, inflammation, centrosome pathologies, microRNAs, cancer initiation and genetics, epigenetics, mitochondrial dysfunctions and apoptosis, cancer stem cells, angiogenesis and progression to metastasis, and treatment strategies including clinical trials related to prostate cancer. Cell & Molecular Biology of Prostate Cancer is one of two companion books comprehensively addressing the biology and clinical aspects of prostate cancer. Prostate Cancer: Molecular & Diagnostic Imaging and Treatment Stategies, the companion volume, discusses both classic and the most recent imaging approaches including analysis of needle biopsies, applications of nanoparticle probes and peptide-based radiopharmaceuticals for detection, early diagnosis and treatment of prostate cancer. Taken together, these volumes form one comprehensive and invaluable contribution to the literature.




Molecular Biology of Cancer: Translation to the Clinic


Book Description

Advances in molecular biology over the last several decades are being steadily applied to our understanding of the molecular biology of cancer, and these advances in knowledge are being translated into the clinical practice of oncology. This volume explores some of the most exciting recent advances in basic research on the molecular biology of cancer and how this knowledge is leading to advances in the diagnosis, treatment, and prevention of cancer. - This series provides a forum for discussion of new discoveries, approaches, and ideas - Contributions from leading scholars and industry experts - Reference guide for researchers involved in molecular biology and related fields










Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease


Book Description

Many people naturally assume that the claims made for foods and nutritional supplements have the same degree of scientific grounding as those for medication, but that is not always the case. The IOM recommends that the FDA adopt a consistent scientific framework for biomarker evaluation in order to achieve a rigorous and transparent process.




Role of Biomarkers in Medicine


Book Description

The use of biomarkers in basic and clinical research has become routine in many areas of medicine. They are accepted as molecular signatures that have been well characterized and repeatedly shown to be capable of predicting relevant disease states or clinical outcomes. In Role of Biomarkers in Medicine, expert researchers in their individual field have reviewed many biomarkers or potential biomarkers in various types of diseases. The topics address numerous aspects of medicine, demonstrating the current conceptual status of biomarkers as clinical tools and as surrogate endpoints in clinical research. This book highlights the current state of biomarkers and will aid scientists and clinicians to develop better and more specific biomarkers for disease management.




Adenocarcinoma of the Prostate


Book Description

Carcinoma of the prostate increasingly dominates the attention of urologists for both scientific and clinical reasons. The search for an explanation and the prediction of the variable behaviour of the malignant prostatic cell continues unabated. The search for more precise tumour staging and more effective treatment is equally vigorous. Editors Andrew Bruce and John Trachtenberg have assembled acknowledged leaders in prostate cancer to present those areas of direct interest to the clinician. There are a number of other topics that might have been considered but most of these, such as experimental tumour models or biochemical factors affecting cell growth, still lack immediate application for the clinician. Carcinoma of the prostate continues to have its highest incidence in the western world, and the difference in comparison with the incidence in the Far East appears to be real and not masked by diagnostic or other factors. A number of other epidemiological aspects need careful analysis: Is the incidence increasing? Is the survival improving? Is the prognosis worse in the younger patient? Epidemiological data are easily misused and misinterpreted so that a precise analysis of the known facts makes an important opening chapter to this book.




Clinical Oncology


Book Description

A must-have reference, this new edition provides practical information on treatment guidelines, details of diagnosis and therapy, and personal recommendations on patient management from experts in the field. Consistently formatted chapters allow for a user-friendly presentation for quick access of key information by the practicing clinician. Completely updated, this new edition includes all of the latest developments in treatment strategies of medical, surgical and radiation oncologists.




Targeted Therapies in Oncology, Second Edition


Book Description

Since the last edition of this book, major advances have been made in our understanding of key pathways that control tumor progression. This has led to the development of new anticancer agents that have the ability to block the activity of proteins involved in neoplastic cell development and proliferation. Targeted Therapies in Oncology, Second Edition provides a concise timely panorama of existing targeted therapies and progress into future anticancer treatments. These therapies notably include: Targeted agents of immune checkpoints Signal-transduction inhibitors Antiangiogenic agents Vascular-disrupting agents Apoptosis modulators Stem cell inhibitors Tumor profiling for drug development The book emphasizes the biology behind this new class of drugs as well as the clinical achievements obtained. The contributors to this volume stand at the cutting edge of cancer research and treatment around the world.




New Insights Into Prostate Cancer: New Biomarkers, Molecular Mechanisms, and Therapeutic Approaches


Book Description

Prostate cancer is the second most common cancer in men, and prognosis varies with age, ethnicity, genetic background, and stage of progression. Disease progression that has been observed in a substantial proportion of patients despite androgen ablation, can arise from many factors, such as the presence of cells that are resistant de novo or acquire resistance induced by androgen-deprivation therapy (ADT) or androgen receptor antagonists.